Consistent with this functional model, two (73, 74) of the four recent studies mentioned above showed that tumor PD-L1 expression can protect only PD-L1+ tumor cells from cytolytic T cell killing in situ, and not PD-L1− cells in trans, conferring a selective growth advantage on PD-L1+ tumor cells. This evidence concerns the gene CD274 and neoplasm.